Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Tan, C. R.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hassoun, H.; Maclachlan, K. H.; Shah, U. A.; Hultcrantz, M.; Hamadeh, I. S.; Giralt, S.; Mailankody, S.; Usmani, S. Z.; Hashmi, H. |
| Abstract Title: | Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 7091 |
| Language: | English |
| ACCESSION: | WOS:001412773800015 |
| DOI: | 10.1182/blood-2024-206511 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work